Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18
| Autor: | Frank J. Taddeo, Laura A. Koutsky, Robert J. Kurman, Anna R. Giuliano, Brigitte M. Ronnett, Janine T. Bryan, Jimmy Yu, Alex Ferenczy, Matti Lehtinen, Radha Railkar, Darron R. Brown, Finn Egil Skjeldestad, Alfred J. Saah, Kathrin U. Jansen, Luisa L. Villa, Rosires Pereira de Andrade, Rocio D. Marchese, Mark H. Stoler, Christian Malm, Sven Eric Olsson, Heather L. Sings, Ronaldo L.R. Costa, Kevin A. Ault, Eliav Barr, Margareta Steinwall, Cosette M. Wheeler, Diane M. Harper, Mark T. Esser, Lisa Lupinacci, Carlos Alberto Petta, Gretchen M. Tamms |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Adult
Adolescent viruses Placebo Antibodies Viral Virus Genital warts Papillomavirus Vaccines Double-Blind Method Medicine Humans Papillomaviridae Cervical cancer Human papillomavirus 16 General Veterinary General Immunology and Microbiology biology Human papillomavirus 18 business.industry Human papillomavirus 11 Immunogenicity Papillomavirus Infections Public Health Environmental and Occupational Health virus diseases Viral Vaccines medicine.disease Human papillomavirus 6 Virology Clinical trial Infectious Diseases Immunology biology.protein Molecular Medicine Female Antibody business |
| Zdroj: | Vaccine. 24(27-28) |
| ISSN: | 0264-410X |
| Popis: | Human papillomavirus (HPV) infection causes cervical cancer and genital warts. Young women (1106) were randomized to receive one of three formulations of a quadrivalent HPV (Types 6/11/16/18) L1 virus-like particle (VLP) vaccine or one of two placebo formulations. The goal was to assess vaccine safety and immunogenicity in baseline HPV 6/11/16 or 18-naïve and previously infected subjects. All three formulations were highly immunogenic. At Month 2 (postdose 1), among women with vaccine-type antibodies at baseline, vaccine-induced anti-HPV responses were approximately 12- to 26-fold higher than those observed in baseline-naïve women, suggesting an anamnestic response. Following an initial, similar sized decline, anti-HPV responses plateaued and remained stable through end-of-study (3.0 years). No vaccine-related serious adverse experiences were reported. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect